PetCaseFinder

Peer-reviewed veterinary case report

Antiviral treatments and recovery in dogs with parvovirus infection

By Ulas, Nergis et al.·Published in Journal of veterinary science·2024·Department of Internal Medicine·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Clinical and inflammatory response to antiviral treatments in dogs with parvoviral enteritis.

Species:
dog

Plain-English summary

A group of 28 dogs diagnosed with parvoviral enteritis, a serious and often fatal disease, received different treatments to see which helped them recover best. All dogs were given standard supportive care, including fluids and antibiotics, but some also received antiviral medications. The dogs that received the antiviral drug recombinant feline interferon omega showed the best improvement in their condition and had a higher survival rate compared to those who only received standard treatment. Overall, adding antiviral treatments could help improve recovery and survival in dogs with this illness.

People also search for: dog parvovirus treatment · canine parvoviral enteritis recovery · antiviral treatment for dogs with parvo

Abstract

BACKGROUND: Canine parvoviral enteritis (CPE) is a fatal disease worldwide. The treatment of CPE is based mainly on supportive and symptomatic treatment. Antiviral addition to the treatment may result in a higher survival. OBJECTIVES: This study evaluated the effects of antiviral treatments with a standardized treatment (ST) on the clinical and inflammatory response of dogs with naturally occurring CPE. METHODS: Twenty-eight dogs with CPE caused by canine parvovirus type 2 were divided randomly into treatment groups. The ST group received fluid, antibiotic, antiemetic, and deworming treatments. The antiviral treatment groups received the same ST with an additional antiviral drug, recombinant feline interferon omega (rFeIFN-&#x3c9;), oseltamivir (OSEL) or famciclovir (FAM). RESULTS: Compared to the healthy control, the tumor necrosis factor-&#x3b1;, interleukin-1&#x3b2;, interferon (IFN)-&#x3b1;, IFN-&#x3b3;, haptoglobin, and C-reactive protein values were high (< 0.05) on day zero. At presentation, mild lymphopenia, neutropenia, and a high neutrophil to lymphocyte (LYM) ratio (NLR) were also observed. Adding rFeIFN-&#x3c9; to the ST produced the best improvement in the clinical score with a decreased NLR, while leucocytes remained low and inflammatory markers stayed high on day three. The survival rates of the groups were 85.7% in ST+IFN, 71.4% in ST+OSEL, 71.4% in ST+FAM, and 57.1% in ST groups on day seven. CONCLUSIONS: Antiviral drugs may be valuable in treating CPE to improve the clinical signs and survival. In addition, the decrease in NLR in favor of LYM may be an indicator of the early prognosis before the improvement of leukocytes, cytokines, and acute phase proteins in CPE.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38311324/